A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in Combination with CAB LA to Standard of Care in Vi

Protocol No

INF-GSK-EMBRACE-HIV

Staff Member

Michael Frank

Phase

Summary

This project is being done to test an antibody that was made in a lab to treat HIV infection.

Objective

HIV Embrace

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL

A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in Combination with CAB LA to Standard of Care in Virologically Suppressed Adults Living with HIV